Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker
المؤلفون المشاركون
Rolfo, Christian
Signorelli, Diego
Giannatempo, Patrizia
Grazia, Giulia
Aiello, Marco Maria
Bertolini, Federica
Mirabile, Aurora
Buti, Sebastiano
Vasile, Enrico
Pisapia, Pasquale
Cona, Maria Silvia
Group, Immune-Oncology YOUNG
Malapelle, Umberto
Scotti, Vieri
المصدر
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-15، 15ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-04-24
دولة النشر
مصر
عدد الصفحات
15
التخصصات الرئيسية
الملخص EN
Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy.
Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a large number of solid tumors, leading to an improvement of progression free survival and overall survival in comparison to standard chemotherapy.
However, across different solid malignancies, the immune-checkpoints inhibitors efficacy is limited to a relative small number of patients and, for this reason, the identification of positive or negative predictive biomarkers represents an urgent need.
Despite the expression of PD-L1 was largely investigated in various malignancies, (i.e., melanoma, head and neck malignancies, urothelial and renal carcinoma, metastatic colorectal cancer, and pancreatic cancer) as a biomarker for ICB treatment-patients selection, it showed an important, but still imperfect, role as positive predictor of response only in nonsmall cell lung cancer (NSCLC).
Importantly, other tumor and/or microenvironments related characteristics are currently under clinical evaluation, in combination or in substitution of PD–L1 expression.
In particular, tumor-infiltrating immune cells, gene expression analysis, mismatch- repair deficiency, and tumor mutational landscape may play a central role in predicting clinical benefits of CTLA-4 and/or PD-1/PD-L1 checkpoint inhibitors.
In this review, we will focus on the clinical evaluation of emerging biomarkers and how these may improve the naïve vision of a single- feature patients-based selection.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Signorelli, Diego& Giannatempo, Patrizia& Grazia, Giulia& Aiello, Marco Maria& Bertolini, Federica& Mirabile, Aurora…[et al.]. 2019. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. BioMed Research International،Vol. 2019, no. 2019, pp.1-15.
https://search.emarefa.net/detail/BIM-1128283
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Signorelli, Diego…[et al.]. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. BioMed Research International No. 2019 (2019), pp.1-15.
https://search.emarefa.net/detail/BIM-1128283
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Signorelli, Diego& Giannatempo, Patrizia& Grazia, Giulia& Aiello, Marco Maria& Bertolini, Federica& Mirabile, Aurora…[et al.]. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. BioMed Research International. 2019. Vol. 2019, no. 2019, pp.1-15.
https://search.emarefa.net/detail/BIM-1128283
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1128283
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر